MedTrace Logo

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

NCT05595889 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-11-29

No results posted yet for this study

Summary

To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.

Conditions

Interventions

DRUG

Surufatinib

250 mg/day p.o. QD

DRUG

Irinotecan

Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Zhiyong He · Fujian Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-09-30
Completion
2025-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05595889 on ClinicalTrials.gov